Business Context and Reporting Period
This Form 8-K is a current report filed by AdventRX Pharmaceuticals, Inc. (not Savara Inc.) on June 17, 2011. The filing addresses a corporate governance event regarding the dismissal of the company's independent registered public accounting firm.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on the change in the registrant's certifying accountant and does not contain financial statement data.
Material Changes
- Dismissal of Auditor: On June 17, 2011, the company dismissed J.H. Cohn LLP as its independent registered public accounting firm.
- Audit Committee Approval: The dismissal was approved by the Audit Committee of the Board of Directors.
- Historical Audit Status: The audit reports for the years ended December 31, 2010, and 2009, did not contain adverse opinions, disclaimers, or qualifications regarding uncertainty, scope, or accounting principles.
- No Disagreements: There were no disagreements with J.H. Cohn on accounting principles, practices, or auditing scope during the fiscal years 2009 and 2010, or through June 17, 2011.
- No Reportable Events: No reportable events requiring disclosure under Item 304(a)(1)(v) of Regulation S-K occurred during the specified periods.
Guidance, Outlook, and Risks
The filing does not provide guidance, outlook, or management commentary on future operations. The primary risk disclosed is the change in the independent auditor, though the company explicitly states there were no underlying disagreements or reportable events necessitating the change.
Investor Verification Checklist
- Verify the identity of the new independent registered public accounting firm appointed to replace J.H. Cohn LLP.
- Review the attached Exhibit 16.1 (Letter from J.H. Cohn LLP) to confirm the auditor's concurrence with the company's disclosures.
- Monitor subsequent filings (e.g., 10-Q or 10-K) for the appointment of the new auditor and any impact on the audit timeline.
- Confirm the company name discrepancy in the request metadata; the filing is for AdventRX Pharmaceuticals, Inc., not Savara Inc.